Latest market price
65.99
-1.13-1.68%
News
Down 1.7% — TransMedics to Present at Upcoming Investor Conferences (prnewswire.com).
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | 17.10 | EPS (ttm) | 3.86 | Insider Own | 4.89% | Shs Outstand | 34.68M | Perf Week | -6.71% |
| Market Cap | 2.29B | Forward P/E | 29.19 | EPS next Y | 2.26 | Insider Trans | -0.49% | Shs Float | 33.56M | Perf Month | -16.09% |
| Enterprise Value | 2.68B | PEG | 0.31 | EPS next Q | 0.30 | Short Float | 26.13% | Perf Quarter | -19.08% | ||
| Income | 151.00M | P/S | 3.42 | EPS this Y | -43.61% | Short Ratio | 10.54 | Perf Half Y | -34.02% | ||
| Sales | 669.00M | P/B | 4.42 | EPS next Y | 54.25% | ROA | 10.36% | Short Interest | 8.77M | Perf YTD | -45.75% |
| Book/sh | 14.94 | P/C | 4.84 | EPS next 5Y | 54.45% | ROE | 32.97% | 52W High | 156.00 -57.70% | Perf Year | -50.87% |
| Cash/sh | 13.64 | P/FCF | 28.96 | EPS past 3/5Y | — | ROIC | 5.87% | 52W Low | 60.11 9.78% | Perf 3Y | 65.55% |
| Dividend Est. | — | EV/EBITDA | 20.64 | Sales past 3/5Y | 86.68% 87.65% | Gross Margin | 58.69% | Volatility | 4.03% 4.79% | Perf 5Y | 140.49% |
| Dividend TTM | — | EV/Sales | 4.01 | EPS Y/Y TTM | 100.00% | Oper. Margin | 12.21% | ATR (14) | 3.64 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 6.07 | Sales Y/Y TTM | 25.75% | Profit Margin | 22.69% | RSI (14) | 28.93 | Recom | 2.31 |
| Dividend Gr. 3/5Y | — | Current Ratio | 6.63 | EPS Q/Q | -52.17% | SMA20 | -11.02% | Beta | 2.15 | Target Price | 99.63 |
| Payout | 0.00% | Debt/Eq | 1.68 | Sales Q/Q | 21.02% | SMA50 | -19.18% | Rel Volume | 1.09 | Prev Close | 67.12 |
| Employees | 898 | LT Debt/Eq | 1.63 | Earnings | Nov 05 | SMA200 | -30.16% | Avg Volume | 827.08K | Price | 65.99 |
| IPO Date | May 02, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -11.20% 3.23% | Net Debt/EBITDA | 3.04 | Volume | 898,075 | Change | -1.68% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-13-26 | Reiterated | Canaccord Genuity | Buy | $95 → $94 |
| Oct-06-26 | Initiated | Barclays | Overweight | $120 |
| Aug-05-26 | Reiterated | Robert W. Baird | $120 → $122 | |
| Aug-05-26 | Reiterated | Canaccord Genuity | Buy | $124 → $95 |
| Aug-05-26 | Reiterated | Stifel Nicolaus | $80 → $65 | |
| Aug-03-26 | Reiterated | Needham | Buy | $142 → $106 |
| Jul-28-26 | Initiated | UBS | Neutral | $80 |
| Jul-06-26 | Reiterated | Evercore ISI Group | Outperform | $155 → $90 |
| Jun-18-26 | Reiterated | Stifel Nicolaus | $75 → $80 | |
| May-26-26 | Reiterated | Stifel Nicolaus | $85 → $75 |
Latest News· Times ET
Nov-01-26
Nov-01-2604:52PM
Oct-30-26
Oct-30-2604:05PM
Oct-29-26
Oct-27-26
Oct-27-2607:00AM
Oct-22-26
Oct-22-2604:05PM
Oct-21-26
Oct-21-2608:05PM
Oct-18-26
Oct-18-2604:32AM
Oct-17-26
Oct-13-26
Oct-13-2611:21AM
Oct-07-26
Oct-02-26
Oct-01-26
Oct-01-2608:08PM
Sep-26-26
Sep-26-2603:56AM
01:44AM
Sep-18-26
Company
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 669 | 605 | 442 | 242 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 276 | 243 | 179 | 88 | — | — | — | — | — | |
| Gross Profit | 392 | 363 | 262 | 154 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 212 | 185 | 169 | 120 | — | — | — | — | — | |
| Research and Development | 93 | 69 | 56 | 63 | — | — | — | — | — | |
| Other Operating Expense | 5 | 0 | 0 | 0 | — | — | — | — | — | |
| Operating Income | 81 | 109 | 37 | -29 | — | — | — | — | — | |
| Interest Expense | 20 | 14 | 14 | 11 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 12 | 13 | 13 | 13 | — | — | — | — | — | |
| Net Income Before Taxes | 72 | 108 | 36 | -27 | — | — | — | — | — | |
| Income Taxes | -79 | -83 | 0 | -2 | — | — | — | — | — | |
| Consolidated Net Income | 151 | 190 | 35 | -25 | — | — | — | — | — | |
| Net Income From Continuing Operations | 151 | 190 | 35 | -25 | — | — | — | — | — | |
| Net Income | 151 | 190 | 35 | -25 | — | — | — | — | — | |
| EPS (Recurring) | 4.42 | 5.60 | 1.07 | -0.77 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 4.42 | 5.60 | 1.07 | -0.77 | — | — | — | — | — | |
| EPS (Diluted) | 3.86 | 4.87 | 1.01 | -0.77 | — | — | — | — | — | |
| EBITDA | 130 | 148 | 70 | -8 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 17.10 | 24.98 | 61.73 | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.45 | 6.84 | 4.66 | 10.76 | — | — | — | — | — | |
| Gross Margin | 58.59 | 60.00 | 59.28 | 63.64 | — | — | — | — | — | |
| Operating Margin | 12.11 | 18.02 | 8.37 | -11.98 | — | — | — | — | — | |
| Net Margin | 22.57 | 31.40 | 7.92 | -10.33 | — | — | — | — | — | |
| Shares Outstanding | 35 | 34 | 33 | 33 | — | — | — | — | — | |
| Market Capitalization | 2,310 | 4,136 | 2,058 | 2,605 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Weill David | Director | Sep 11 '26 | Buy | 81.63 | 1,336 | 109,058 | 16,392 | Sep 14 |
| Gunderson Thomas J. | Director | Jun 15 '26 | Option Exercise | 2.21 | 19,285 | 42,620 | 26,266 | Jun 17 |
| Gunderson Thomas J. | Director | Jun 15 '26 | Sale | 75.06 | 9,624 | 722,377 | 16,642 | Jun 17 |
| Weill David | Director | Mar 04 '26 | Option Exercise | 14.20 | 3,571 | 50,708 | 15,705 | Mar 06 |
| Lovell Stephanie | Director | Mar 04 '26 | Sale | 149.62 | 1,193 | 178,497 | 2,866 | Mar 06 |
| Weill David | Director | Mar 04 '26 | Sale | 146.82 | 3,571 | 524,294 | 12,134 | Mar 06 |
| Hernandez Gerardo | Chief Financial Officer | Mar 04 '26 | Option Exercise | 71.17 | 7,236 | 515,001 | 20,601 | Mar 04 |
| Hernandez Gerardo | Chief Financial Officer | Mar 04 '26 | Sale | 147.21 | 5,912 | 870,306 | 14,689 | Mar 04 |
| Corcoran Nicholas | Officer | Mar 02 '26 | Sale | 139.12 | 2,966 | 412,630 | 29,831 | Mar 04 |
| Ranganath Anil P. | Officer | Mar 02 '26 | Sale | 139.12 | 864 | 120,200 | 13,091 | Mar 04 |
| Hernandez Gerardo | Chief Financial Officer | Mar 02 '26 | Sale | 139.12 | 375 | 52,170 | 14,689 | Mar 04 |
| Hernandez Gerardo | Chief Financial Officer | Dec 04 '25 | Sale | 139.62 | 920 | 128,450 | 15,064 | Dec 05 |
| Weill David | Director | Dec 03 '25 | Sale | 138.64 | 5,000 | 693,200 | 12,134 | Dec 05 |
| Weill David | Director | Dec 03 '25 | Option Exercise | 14.20 | 5,000 | 71,000 | 17,134 | Dec 05 |
| Ranganath Anil P. | Officer | Nov 25 '25 | Option Exercise | 93.88 | 3,000 | 281,640 | 16,955 | Nov 26 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.